Title,Decision,Note,frac_eval_innovative,frac_eval_innovative(Actual Value),Disease_Category,Disease_Category (Actual Value),HT_Category,HT_Category (Actual Value),Number of Patients,Number of Patients (Actual Value),Number of RCTs,Number of RCTs (Actual Value),Number of Obserational Studies,Number of Observational Studies (Actual Value),Note
Baricitinib for treating severe alopecia areata,Rejected,In sample test,1,1,,,,,1200,1200,2,2,,,
Dupilumab for treating moderate to severe prurigo nodularis,Rejected,In sample test,1,1,,,,,311,311,2,2,,,
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer,Rejected,In sample test,0.67,0.67,,,,,296,296,1,1,,,
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments,Rejected,In sample test,1,1,,,,,831,831,1,1,,,
Tixagevimab plus cilgavimab for preventing COVID-19,Rejected,In sample test,0.5,1,,,,,5150,5150,2,1,,,
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours,Approved,In sample test,1,1,,,,,234,234,2,2,,,
Bevacizumab gamma for treating wet age-related macular degeneration,Approved,In sample test,0.5,0.5,,,,,228,228,1,1,,,
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer,Approved,In sample test,N/A,N/A,,,,,661,1352,8,0,,,
Eplontersen for treating hereditary transthyretin-related amyloidosis,Approved,In sample test,1,1,,,,,361,166,2,1,,,
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,Approved,In sample test,0,0,,,,,1172,1172,1,1,,,
"Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis",Approved,,N/A,N/A,,,,,N/A,N/A,N/A,3,,,Can only access via Adobe; the number of patients is blocked
"Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",Approved,,1,1,,,,,5637,5637,1,1,,,
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,Rejected,,1,1,,,,,N/A,2213,N/A,2,,,"Doesn't exist the section ""study group"". Difficult to find out number of patients"
Acalabrutinib for treating chronic lymphocytic leukaemia,Conditional,,0.67,1,,,,,310,1211,2,3,,,Involves many pages
"Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed",Rejected,,1,1,,,,,N/A,N/A,N/A,N/A,,,No submission
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer,Approved,,1,1,,,,,247,248,1,1,,,
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,Rejected,,N/A,N/A,,,,,N/A,N/A,N/A,N/A,,,No submission
Anakinra for treating Still’s disease,Approved,,1,1,,,,,204,61,1,3,,,Involves many pages
Arsenic trioxide for treating acute promyelocytic leukaemia,Approved,,1,1,,,,,451,N/A,3,3,,,
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer,Approved,,0.5,0.5,,,,,1200,1200,1,1,,,
Avapritinib for treating advanced systemic mastocytosis,Approved,,1,1,,,,,0,0,2,0,,,
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal),Rejected,,1,1,,,,,56,0,1,0,,,Cannot recognize whether a trial is RCT or not since not enough pages are provided to GPT
Avatrombopag for treating primary chronic immune thrombocytopenia,Approved,,0.5,0.5,,,,,97,136,3,3,,,
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma,Rejected,,N/A,1,,,,,359,0,1,0,,,
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts,Rejected,,N/A,N/A,,,,,488,488,1,1,,,
Beta interferons and glatiramer acetate for treating multiple sclerosis,Rejected,,N/A,N/A,,,,,N/A,N/A,N/A,N/A,,,No submission paper
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal),Rejected,,0.75,1,,,,,1014,1014,2,2,,,
Baricitinib_for_moderate_to_severe_rheumatoid_arthritis.pdf,Conditional,,N/A,N/A,,,,,3700,2518,4,3,,,
Belumosudil_for_treating_chronic_graft-versus-host_disease_after_2_or_more_systemic_treatments_in...,Conditional,,N/A,N/A,,,,,N/A,N/A,N/A,N/A,,,No Submission Paper
Brolucizumab_for_treating_wet_age-related_macular_degeneration.pdf,Conditional,,0,0,,,,,1950,1906,3,3,,,Mentioned in a different section
Cabozantinib_for_treating_medullary_thyroid_cancer.pdf,Conditional,,1,N/A,,,,,331,331,1,1,,,
Cannabidiol_with_clobazam_for_treating_seizures_associated_with_Dravet_syndrome.pdf,Conditional,,0.5,0.5,,,,,N/A,318,N/A,2,,,
Dapagliflozin_in_triple_therapy_for_treating_type_2_diabetes.pdf,Approved,,N/A,N/A,,,,,219,219,1,1,,,
Daridorexant_for_treating_long-term_insomnia.pdf,Approved,,N/A,N/A,,,,,N/A,1734,N/A,2,,,
"Dasatinib,_nilotinib_and_high-dose_imatinib_for_treating_imatinib-resistant_or_intolerant_chronic...",Approved,,N/A,N/A,,,,,N/A,N/A,N/A,N/A,,,No submission paper
Degarelix_for_treating_advanced_hormone-dependent_prostate_cancer.pdf,Conditional,,N/A,N/A,,,,,N/A,N/A,N/A,N/A,,,No submission paper
Dimethyl_fumarate_for_treating_moderate_to_severe_plaque_psoriasis.pdf,Approved,,N/A,N/A,,,,,690,690,1,1,,,
Elbasvir–grazoprevir_for_treating_chronic_hepatitis_C.pdf,Conditional,,N/A,N/A,,,,,1584,1840,7,7,,,
Encorafenib_with_binimetinib_for_unresectable_or_metastatic_BRAF_V600_mutation-positive_melanoma.pdf,Conditional,,0.5,0.5,,,,,576,576,4,1,,,
Eribulin_for_treating_locally_advanced_or_metastatic_breast_cancer_after_2_or_more_chemotherapy_r...,Approved,,N/A,N/A,,,,,1710,1864,3,2,,,
Everolimus_and_sunitinib_for_treating_unresectable_or_metastatic_neuroendocrine_tumours_in_people...,Approved,,N/A,N/A,,,,,N/A,N/A,N/A,N/A,,,No submission paper
Ozanimod for treating relapsing–remitting multiple sclerosis,Rejected,,0.5,0.5,,,,,2408,2917,3,3,,,
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment,Approved,,1,1,,,,,20,0,0,0,,,No submission paper
Vutrisiran for treating hereditary transthyretin-related amyloidosis,Conditional,,N/A,N/A,,,,,164,389,2,2,,,The number of trials in another trial is in a page that is far from the typical place
Voclosporin with mycophenolate mofetil for treating lupus nephritis,Approved,,N/A,0.67,,,,,880,906,3,3,,,
Vismodegib for treating basal cell carcinoma,Rejected,,N/A,N/A,,,,,0,0,0,0,,,
Vibegron for treating symptoms of overactive bladder syndrome,Approved,,N/A,N/A,,,,,4612,4122,8,8,,,
Vandetanib for treating medullary thyroid cancer,Rejected,,N/A,N/A,,,,,N/A,N/A,N/A,N/A,,,No submission paper
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy,Rejected,,1,1,,,,,437,557,2,1,,,
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma,Rejected,,1,1,,,,,0,0,0,0,,,